Rowe SM - Search Results

1

Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis.

Baker E, Harris WT, Rowe SM, Rutland SB, Oates GR. Baker E, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Jul;20(4):612-617. doi: 10.1016/j.jcf.2020.09.011. Epub 2020 Oct 3. J Cyst Fibros. 2021. PMID: 33023836 Free PMC article.

2

Bioelectric effects of quinine on polarized airway epithelial cells.

Bates E, Miller S, Alexander M, Mazur M, Fortenberry JA, Bebok Z, Sorscher EJ, Rowe SM. Bates E, et al. Among authors: rowe sm. J Cyst Fibros. 2007 Sep;6(5):351-9. doi: 10.1016/j.jcf.2007.01.001. Epub 2007 Feb 27. J Cyst Fibros. 2007. PMID: 17329172 Free PMC article.

3

Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.

Troxler RB, Hoover WC, Britton LJ, Gerwin AM, Rowe SM. Troxler RB, et al. Among authors: rowe sm. Pediatr Pulmonol. 2012 Nov;47(11):1113-22. doi: 10.1002/ppul.22543. Epub 2012 Apr 11. Pediatr Pulmonol. 2012. PMID: 22496040 Free PMC article.

4

A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.

Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, Byan-Parker S, Grizzle W, Sorscher EJ, Dransfield MT, Rowe SM. Sloane PA, et al. Among authors: rowe sm. PLoS One. 2012;7(6):e39809. doi: 10.1371/journal.pone.0039809. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768130 Free PMC article.

5

Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.

Dransfield MT, Wilhelm AM, Flanagan B, Courville C, Tidwell SL, Raju SV, Gaggar A, Steele C, Tang LP, Liu B, Rowe SM. Dransfield MT, et al. Among authors: rowe sm. Chest. 2013 Aug;144(2):498-506. doi: 10.1378/chest.13-0274. Chest. 2013. PMID: 23538783 Free PMC article.

6

Evaluating the predictive ability of sweat chloride.

Heltshe SL, Rowe SM, Mayer-Hamblett N. Heltshe SL, et al. Among authors: rowe sm. J Cyst Fibros. 2014 Jan;13(1):118. doi: 10.1016/j.jcf.2013.07.002. Epub 2013 Aug 3. J Cyst Fibros. 2014. PMID: 23920003 Free article. No abstract available.

7

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

Rowe SM, Liu B, Hill A, Hathorne H, Cohen M, Beamer JR, Accurso FJ, Dong Q, Ordoñez CL, Stone AJ, Olson ER, Clancy JP; VX06-770-101 Study Group. Rowe SM, et al. PLoS One. 2013 Jul 26;8(7):e66955. doi: 10.1371/journal.pone.0066955. Print 2013. PLoS One. 2013. PMID: 23922647 Free PMC article. Clinical Trial.

8

Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Chaaban MR, Kejner A, Rowe SM, Woodworth BA. Chaaban MR, et al. Among authors: rowe sm. Am J Rhinol Allergy. 2013 Sep-Oct;27(5):387-95. doi: 10.2500/ajra.2013.27.3919. Am J Rhinol Allergy. 2013. PMID: 24119602 Free PMC article. Review.

9

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Accurso FJ, Van Goor F, Zha J, Stone AJ, Dong Q, Ordonez CL, Rowe SM, Clancy JP, Konstan MW, Hoch HE, Heltshe SL, Ramsey BW, Campbell PW, Ashlock MA. Accurso FJ, et al. Among authors: rowe sm. J Cyst Fibros. 2014 Mar;13(2):139-47. doi: 10.1016/j.jcf.2013.09.007. J Cyst Fibros. 2014. PMID: 24660233 Free PMC article. Clinical Trial.

10

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Rowe SM, et al. Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84. doi: 10.1164/rccm.201404-0703OC. Am J Respir Crit Care Med. 2014. PMID: 24927234 Free PMC article.

11

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. Boyle MP, et al. Among authors: rowe sm. Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24. Lancet Respir Med. 2014. PMID: 24973281 Clinical Trial.

12

Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Heltshe SL, Mayer-Hamblett N, Burns JL, Khan U, Baines A, Ramsey BW, Rowe SM; GOAL (the G551D Observation-AL) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Heltshe SL, et al. Among authors: rowe sm. Clin Infect Dis. 2015 Mar 1;60(5):703-12. doi: 10.1093/cid/ciu944. Epub 2014 Nov 25. Clin Infect Dis. 2015. PMID: 25425629 Free PMC article.

13

Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation.

Yousef S, Solomon GM, Brody A, Rowe SM, Colin AA. Yousef S, et al. Among authors: rowe sm. Chest. 2015 Mar;147(3):e79-e82. doi: 10.1378/chest.14-1198. Chest. 2015. PMID: 25732475

14

Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.

Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A. Bratcher PE, et al. Among authors: rowe sm. J Cyst Fibros. 2016 Jan;15(1):67-73. doi: 10.1016/j.jcf.2015.02.010. Epub 2015 Mar 11. J Cyst Fibros. 2016. PMID: 25769931 Free PMC article.

15

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Wainwright CE, et al. Among authors: rowe sm. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17. N Engl J Med. 2015. PMID: 25981758 Free PMC article. Clinical Trial.

16

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group. Moss RB, et al. Among authors: rowe sm. Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9. Lancet Respir Med. 2015. PMID: 26070913 Free PMC article. Clinical Trial.

17

Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.

Birket SE, Chu KK, Houser GH, Liu L, Fernandez CM, Solomon GM, Lin V, Shastry S, Mazur M, Sloane PA, Hanes J, Grizzle WE, Sorscher EJ, Tearney GJ, Rowe SM. Birket SE, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2016 May 15;310(10):L928-39. doi: 10.1152/ajplung.00395.2015. Epub 2016 Mar 11. Am J Physiol Lung Cell Mol Physiol. 2016. PMID: 26968770 Free PMC article.

18

New and emerging targeted therapies for cystic fibrosis.

Quon BS, Rowe SM. Quon BS, et al. Among authors: rowe sm. BMJ. 2016 Mar 30;352:i859. doi: 10.1136/bmj.i859. BMJ. 2016. PMID: 27030675 Free PMC article. Review.

19

Pilot evaluation of ivacaftor for chronic bronchitis.

Solomon GM, Hathorne H, Liu B, Raju SV, Reeves G, Acosta EP, Dransfield MT, Rowe SM. Solomon GM, et al. Among authors: rowe sm. Lancet Respir Med. 2016 Jun;4(6):e32-3. doi: 10.1016/S2213-2600(16)30047-9. Epub 2016 May 16. Lancet Respir Med. 2016. PMID: 27185048 Free PMC article. Clinical Trial. No abstract available.

20

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.

Wells JM, Farris RF, Gosdin TA, Dransfield MT, Wood ME, Bell SC, Rowe SM. Wells JM, et al. Among authors: rowe sm. Lancet Respir Med. 2016 Aug;4(8):636-645. doi: 10.1016/S2213-2600(16)30105-9. Epub 2016 Jun 10. Lancet Respir Med. 2016. PMID: 27298019 Free PMC article.

21

The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.

Raju SV, Lin VY, Liu L, McNicholas CM, Karki S, Sloane PA, Tang L, Jackson PL, Wang W, Wilson L, Macon KJ, Mazur M, Kappes JC, DeLucas LJ, Barnes S, Kirk K, Tearney GJ, Rowe SM. Raju SV, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2017 Jan;56(1):99-108. doi: 10.1165/rcmb.2016-0226OC. Am J Respir Cell Mol Biol. 2017. PMID: 27585394 Free PMC article.

22

Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.

Mutyam V, Libby EF, Peng N, Hadjiliadis D, Bonk M, Solomon GM, Rowe SM. Mutyam V, et al. Among authors: rowe sm. J Cyst Fibros. 2017 Jan;16(1):24-29. doi: 10.1016/j.jcf.2016.09.005. Epub 2016 Oct 1. J Cyst Fibros. 2017. PMID: 27707539 Free PMC article.

23

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group. Rowe SM, et al. Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC. Ann Am Thorac Soc. 2017. PMID: 27898234 Free PMC article. Clinical Trial.

24

A little CFTR can change a lot: slowing cystic fibrosis progression.

Rowe SM. Rowe SM. Lancet Respir Med. 2017 Feb;5(2):86-87. doi: 10.1016/S2213-2600(16)30465-9. Epub 2016 Dec 21. Lancet Respir Med. 2017. PMID: 28011036 No abstract available.

25

Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor.

Stalvey MS, Pace J, Niknian M, Higgins MN, Tarn V, Davis J, Heltshe SL, Rowe SM. Stalvey MS, et al. Among authors: rowe sm. Pediatrics. 2017 Feb;139(2):e20162522. doi: 10.1542/peds.2016-2522. Pediatrics. 2017. PMID: 28143919 Free PMC article. Clinical Trial.

26

A multiple reader scoring system for Nasal Potential Difference parameters.

Solomon GM, Liu B, Sermet-Gaudelus I, Fajac I, Wilschanski M, Vermeulen F, Rowe SM. Solomon GM, et al. Among authors: rowe sm. J Cyst Fibros. 2017 Sep;16(5):573-578. doi: 10.1016/j.jcf.2017.04.011. Epub 2017 Apr 29. J Cyst Fibros. 2017. PMID: 28465124 Free PMC article.

27

Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis.

Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Rowe SM, et al. N Engl J Med. 2017 Nov 23;377(21):2024-2035. doi: 10.1056/NEJMoa1709847. Epub 2017 Nov 3. N Engl J Med. 2017. PMID: 29099333 Free PMC article. Clinical Trial.

28

MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.

Lutful Kabir F, Ambalavanan N, Liu G, Li P, Solomon GM, Lal CV, Mazur M, Halloran B, Szul T, Gerthoffer WT, Rowe SM, Harris WT. Lutful Kabir F, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2018 Mar 1;197(5):632-643. doi: 10.1164/rccm.201704-0732OC. Am J Respir Crit Care Med. 2018. PMID: 29232160 Free PMC article.

29

Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.

Heltshe SL, Rowe SM, Skalland M, Baines A, Jain M; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Heltshe SL, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2018 Jun 1;197(11):1483-1486. doi: 10.1164/rccm.201710-2046LE. Am J Respir Crit Care Med. 2018. PMID: 29256624 Free PMC article. No abstract available.

30

Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer.

Guimbellot JS, Acosta EP, Rowe SM. Guimbellot JS, et al. Among authors: rowe sm. Pediatr Pulmonol. 2018 May;53(5):E6-E8. doi: 10.1002/ppul.23971. Epub 2018 Feb 28. Pediatr Pulmonol. 2018. PMID: 29488691 Free PMC article.

31

Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

Ratjen F, Klingel M, Black P, Powers MR, Grasemann H, Solomon M, Sagel SD, Donaldson SH, Rowe SM, Rosenfeld M. Ratjen F, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2018 Aug 15;198(4):526-528. doi: 10.1164/rccm.201802-0243LE. Am J Respir Crit Care Med. 2018. PMID: 29614238 Free PMC article. No abstract available.

32

Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations.

Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM; GOALe(2) Investigators. Guimbellot J, et al. Among authors: rowe sm. J Cyst Fibros. 2019 Jan;18(1):102-109. doi: 10.1016/j.jcf.2018.04.004. Epub 2018 Apr 21. J Cyst Fibros. 2019. PMID: 29685811 Free PMC article.

33

EMPIRE-CF: A phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis - Study design and patient demographics.

Elborn JS, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM. Elborn JS, et al. Among authors: rowe sm. Contemp Clin Trials. 2018 Sep;72:86-94. doi: 10.1016/j.cct.2018.07.014. Epub 2018 Jul 26. Contemp Clin Trials. 2018. PMID: 30056216 Free article.

34

VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL; VX16-445-001 Study Group. Keating D, et al. Among authors: rowe sm. N Engl J Med. 2018 Oct 25;379(17):1612-1620. doi: 10.1056/NEJMoa1807120. Epub 2018 Oct 18. N Engl J Med. 2018. PMID: 30334692 Free PMC article. Clinical Trial.

35

VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.

Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM; VX16-659-101 Study Group. Davies JC, et al. Among authors: rowe sm. N Engl J Med. 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119. Epub 2018 Oct 18. N Engl J Med. 2018. PMID: 30334693 Free PMC article. Clinical Trial.

36

The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.

Shei RJ, Peabody JE, Kaza N, Rowe SM. Shei RJ, et al. Among authors: rowe sm. Curr Opin Pharmacol. 2018 Dec;43:152-165. doi: 10.1016/j.coph.2018.09.007. Epub 2018 Oct 16. Curr Opin Pharmacol. 2018. PMID: 30340955 Free PMC article. Review.

37

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM. Sermet-Gaudelus I, et al. Among authors: rowe sm. J Cyst Fibros. 2019 Jul;18(4):536-542. doi: 10.1016/j.jcf.2018.10.015. Epub 2018 Nov 19. J Cyst Fibros. 2019. PMID: 30467074 Free PMC article.

38

Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.

McCormick J, Cho DY, Lampkin B, Richman J, Hathorne H, Rowe SM, Woodworth BA. McCormick J, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2019 Mar;9(3):292-297. doi: 10.1002/alr.22251. Epub 2018 Nov 24. Int Forum Allergy Rhinol. 2019. PMID: 30472785 Free PMC article.

39

Colocolonic intussusception in an adult cystic fibrosis patient.

Timothy Adewale A, Rowe SM, Solomon GM. Timothy Adewale A, et al. Among authors: rowe sm. J Cyst Fibros. 2019 Mar;18(2):e11-e13. doi: 10.1016/j.jcf.2018.11.013. Epub 2018 Nov 29. J Cyst Fibros. 2019. PMID: 30503033 Free PMC article.

40

Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis.

Oates GR, Stepanikova I, Rowe SM, Gamble S, Gutierrez HH, Harris WT. Oates GR, et al. Among authors: rowe sm. Respir Care. 2019 Feb;64(2):176-181. doi: 10.4187/respcare.06436. Epub 2018 Dec 11. Respir Care. 2019. PMID: 30538158 Free PMC article.

41

Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.

Donaldson SH, Laube BL, Corcoran TE, Bhambhvani P, Zeman K, Ceppe A, Zeitlin PL, Mogayzel PJ Jr, Boyle M, Locke LW, Myerburg MM, Pilewski JM, Flanagan B, Rowe SM, Bennett WD. Donaldson SH, et al. Among authors: rowe sm. JCI Insight. 2018 Dec 20;3(24):e122695. doi: 10.1172/jci.insight.122695. JCI Insight. 2018. PMID: 30568035 Free PMC article.

42

The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report.

Johns JD, Rowe SM. Johns JD, et al. Among authors: rowe sm. BMC Gastroenterol. 2019 Jul 11;19(1):123. doi: 10.1186/s12876-019-1044-7. BMC Gastroenterol. 2019. PMID: 31296159 Free PMC article.

43

Area Deprivation as a Risk Factor for Methicillin-resistant Staphylococcus aureus Infection in Pediatric Cystic Fibrosis.

Oates GR, Harris WT, Rowe SM, Solomon GM, Dey S, Zhu A, Hoover WC, Gutierrez HH. Oates GR, et al. Among authors: rowe sm. Pediatr Infect Dis J. 2019 Nov;38(11):e285-e289. doi: 10.1097/INF.0000000000002419. Pediatr Infect Dis J. 2019. PMID: 31568067 Free PMC article.

44

The future of cystic fibrosis care: a global perspective.

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, Naehrlich L, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. Bell SC, et al. Among authors: rowe sm. Lancet Respir Med. 2020 Jan;8(1):65-124. doi: 10.1016/S2213-2600(19)30337-6. Epub 2019 Sep 27. Lancet Respir Med. 2020. PMID: 31570318 Free PMC article. Review.

45

Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.

Harris JK, Wagner BD, Zemanick ET, Robertson CE, Stevens MJ, Heltshe SL, Rowe SM, Sagel SD. Harris JK, et al. Among authors: rowe sm. Ann Am Thorac Soc. 2020 Feb;17(2):212-220. doi: 10.1513/AnnalsATS.201907-493OC. Ann Am Thorac Soc. 2020. PMID: 31604026 Free PMC article.

46

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Heijerman HGM, et al. Among authors: rowe sm. Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31. Lancet. 2019. PMID: 31679946 Free PMC article. Clinical Trial.

47

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R; VX17-445-102 Study Group. Middleton PG, et al. Among authors: rowe sm. N Engl J Med. 2019 Nov 7;381(19):1809-1819. doi: 10.1056/NEJMoa1908639. Epub 2019 Oct 31. N Engl J Med. 2019. PMID: 31697873 Free PMC article. Clinical Trial.

48

Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy.

Guimbellot JS, Ryan KJ, Anderson JD, Liu Z, Kersh L, Esther CR, Rowe SM, Acosta EP. Guimbellot JS, et al. Among authors: rowe sm. J Cyst Fibros. 2020 Sep;19(5):742-745. doi: 10.1016/j.jcf.2020.01.011. Epub 2020 Feb 7. J Cyst Fibros. 2020. PMID: 32044246 Free PMC article.

49

Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis.

Oates GR, Baker E, Rowe SM, Gutierrez HH, Schechter MS, Morgan W, Harris WT. Oates GR, et al. Among authors: rowe sm. J Cyst Fibros. 2020 Sep;19(5):783-790. doi: 10.1016/j.jcf.2020.02.004. Epub 2020 Feb 17. J Cyst Fibros. 2020. PMID: 32081643 Free PMC article.

50

Ataluren/ivacaftor combination therapy: Two N-of-1 trials in cystic fibrosis patients with nonsense mutations.

Peabody Lever JE, Mutyam V, Hathorne HY, Peng N, Sharma J, Edwards LJ, Rowe SM. Peabody Lever JE, et al. Among authors: rowe sm. Pediatr Pulmonol. 2020 Jul;55(7):1838-1842. doi: 10.1002/ppul.24764. Epub 2020 Apr 13. Pediatr Pulmonol. 2020. PMID: 32281737 Free PMC article.

51

Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis.

Liu Z, Anderson JD, Deng L, Mackay S, Bailey J, Kersh L, Rowe SM, Guimbellot JS. Liu Z, et al. Among authors: rowe sm. Genes (Basel). 2020 May 29;11(6):603. doi: 10.3390/genes11060603. Genes (Basel). 2020. PMID: 32485957 Free PMC article.

52

Pharmacological approaches for targeting cystic fibrosis nonsense mutations.

Sharma J, Keeling KM, Rowe SM. Sharma J, et al. Among authors: rowe sm. Eur J Med Chem. 2020 Aug 15;200:112436. doi: 10.1016/j.ejmech.2020.112436. Epub 2020 May 21. Eur J Med Chem. 2020. PMID: 32512483 Free PMC article. Review.

53

Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.

Shaw M, Khan U, Clancy JP, Donaldson SH, Sagel SD, Rowe SM, Ratjen F; PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Shaw M, et al. Among authors: rowe sm. J Cyst Fibros. 2020 Nov;19(6):931-933. doi: 10.1016/j.jcf.2020.05.010. Epub 2020 Jun 6. J Cyst Fibros. 2020. PMID: 32513528 Free PMC article.

54

CFTR targeted therapies: recent advances in cystic fibrosis and possibilities in other diseases of the airways.

Patel SD, Bono TR, Rowe SM, Solomon GM. Patel SD, et al. Among authors: rowe sm. Eur Respir Rev. 2020 Jun 16;29(156):190068. doi: 10.1183/16000617.0068-2019. Print 2020 Jun 30. Eur Respir Rev. 2020. PMID: 32554756 Free PMC article. Review.

55

Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.

Birket SE, Davis JM, Fernandez-Petty CM, Henderson AG, Oden AM, Tang L, Wen H, Hong J, Fu L, Chambers A, Fields A, Zhao G, Tearney GJ, Sorscher EJ, Rowe SM. Birket SE, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2020 Nov 1;202(9):1271-1282. doi: 10.1164/rccm.202002-0369OC. Am J Respir Crit Care Med. 2020. PMID: 32584141 Free PMC article.

56

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.

Schwarz C, Sutharsan S, Epaud R, Klingsberg RC, Fischer R, Rowe SM, Audhya PK, Ahluwalia N, You X, Ferro TJ, Duncan ME, Bruinsma BG. Schwarz C, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Mar;20(2):228-233. doi: 10.1016/j.jcf.2020.06.001. Epub 2020 Jun 23. J Cyst Fibros. 2021. PMID: 32586736 Free PMC article. Clinical Trial.

57

Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.

Sagel SD, Khan U, Heltshe SL, Clancy JP, Borowitz D, Gelfond D, Donaldson SH, Moran A, Ratjen F, VanDalfsen JM, Rowe SM. Sagel SD, et al. Among authors: rowe sm. Ann Am Thorac Soc. 2021 Jan;18(1):75-83. doi: 10.1513/AnnalsATS.202002-144OC. Ann Am Thorac Soc. 2021. PMID: 32644818 Free PMC article. Clinical Trial.

58

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients.

Moheet A, Beisang D, Zhang L, Sagel SD, VanDalfsen JM, Heltshe SL, Frederick C, Mann M, Antos N, Billings J, Rowe SM, Moran A; PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Moheet A, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Mar;20(2):333-338. doi: 10.1016/j.jcf.2020.09.001. Epub 2020 Sep 8. J Cyst Fibros. 2021. PMID: 32917547 Free PMC article.

59

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).

Kazani S, Rowlands DJ, Bottoli I, Milojevic J, Alcantara J, Jones I, Kulmatycki K, Machineni S, Mostovy L, Nicholls I, Nick JA, Rowe SM, Simmonds NJ, Vegesna R, Verheijen J, Danahay H, Gosling M, Ayalavajjala PS, Salman M, Strieter R. Kazani S, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Mar;20(2):250-256. doi: 10.1016/j.jcf.2020.11.002. Epub 2020 Dec 6. J Cyst Fibros. 2021. PMID: 33293212 Free PMC article.

60

Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series.

O'Connor KE, Goodwin DL, NeSmith A, Garcia B, Mingora C, Ladores SL, Rowe SM, Krick S, Solomon GM. O'Connor KE, et al. Among authors: rowe sm. J Cyst Fibros. 2021 May;20(3):399-401. doi: 10.1016/j.jcf.2020.12.011. Epub 2021 Jan 19. J Cyst Fibros. 2021. PMID: 33353860 Free PMC article.

61

Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.

Zemanick ET, Konstan MW, VanDevanter DR, Rowe SM, Clancy JP, Odem-Davis K, Skalland M, Mayer-Hamblett N. Zemanick ET, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Nov;20(6):965-971. doi: 10.1016/j.jcf.2021.01.011. Epub 2021 Feb 8. J Cyst Fibros. 2021. PMID: 33573995 Free PMC article.

62

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080

63

PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy.

Nichols DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Sagel SD, Rosenfeld M, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Kirby S, VanDalfsen JM, Clancy JP, Rowe SM. Nichols DP, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Mar;20(2):205-212. doi: 10.1016/j.jcf.2021.02.003. Epub 2021 Feb 19. J Cyst Fibros. 2021. PMID: 33619012 Free PMC article. Review.

64

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.

Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. Zemanick ET, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2021 Jun 15;203(12):1522-1532. doi: 10.1164/rccm.202102-0509OC. Am J Respir Crit Care Med. 2021. PMID: 33734030 Free PMC article. Clinical Trial.

65

Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study.

Donaldson SH, Laube BL, Mogayzel P, Corcoran TE, Pilewski JM, Ceppe A, Wu J, Bhambhvani PG, Ratjen F, Sagel SD, Clancy JP, Rowe SM, Bennett WD. Donaldson SH, et al. Among authors: rowe sm. J Cyst Fibros. 2022 Jan;21(1):143-145. doi: 10.1016/j.jcf.2021.05.004. Epub 2021 May 31. J Cyst Fibros. 2022. PMID: 34083123 Free PMC article.

66

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation.

Oren YS, Irony-Tur Sinai M, Golec A, Barchad-Avitzur O, Mutyam V, Li Y, Hong J, Ozeri-Galai E, Hatton A, Leibson C, Carmel L, Reiter J, Sorscher EJ, Wilton SD, Kerem E, Rowe SM, Sermet-Gaudelus I, Kerem B. Oren YS, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Sep;20(5):865-875. doi: 10.1016/j.jcf.2021.06.003. Epub 2021 Jul 2. J Cyst Fibros. 2021. PMID: 34226157 Free PMC article.

67

Cessation of smoke exposure improves pediatric CF outcomes: Longitudinal analysis of CF Foundation Patient Registry data.

Oates GR, Baker E, Collaco JM, Rowe SM, Rutland SB, Fowler CM, Harris WT. Oates GR, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Jul;20(4):618-624. doi: 10.1016/j.jcf.2021.06.014. Epub 2021 Jul 17. J Cyst Fibros. 2021. PMID: 34281808 Free PMC article.

68

Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.

Derichs N, Taylor-Cousar JL, Davies JC, Fajac I, Tullis E, Nazareth D, Downey DG, Rosenbluth D, Malfroot A, Saunders C, Jensen R, Solomon GM, Vermeulen F, Kaiser A, Willmann S, Saleh S, Droebner K, Sandner P, Bear CE, Hoffmann A, Ratjen F, Rowe SM; Rio-CF Study Group. Derichs N, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Nov;20(6):1018-1025. doi: 10.1016/j.jcf.2021.07.015. Epub 2021 Aug 19. J Cyst Fibros. 2021. PMID: 34419414 Free article. Clinical Trial.

69

Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.

Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Barry PJ, et al. Among authors: rowe sm. N Engl J Med. 2021 Aug 26;385(9):815-825. doi: 10.1056/NEJMoa2100665. N Engl J Med. 2021. PMID: 34437784 Free PMC article. Clinical Trial.

70

Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis.

Elborn JS, Konstan MW, Taylor-Cousar JL, Fajac I, Horsley A, Sutharsan S, Aaron SD, Daines CL, Uluer A, Downey DG, Lucidi VV, Ahuja S, Springman E, Mershon J, Grosswald R, Rowe SM; EMPIRE-CF study group. Elborn JS, et al. Among authors: rowe sm. J Cyst Fibros. 2021 Nov;20(6):1026-1034. doi: 10.1016/j.jcf.2021.08.007. Epub 2021 Sep 17. J Cyst Fibros. 2021. PMID: 34538755 Free PMC article. Clinical Trial.

71

Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa-induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epithelia.

Cho DY, Zhang S, Skinner DF, Lim DJ, Banks C, Grayson JW, Tearney GJ, Rowe SM, Woodworth BA. Cho DY, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2022 May;12(5):690-698. doi: 10.1002/alr.22907. Epub 2021 Oct 26. Int Forum Allergy Rhinol. 2022. PMID: 34704673 Free PMC article.

72

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.

Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM; PROMISE Study group. Nichols DP, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC. Am J Respir Crit Care Med. 2022. PMID: 34784492 Free PMC article.

73

Reply to Martin et al.: Change in Lung Function after Initiation of Elexacaftor-Tezacaftor-Ivacaftor: Do Not Forget Anatomy!

Nichols DP, Rowe SM. Nichols DP, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2022 Jun 1;205(11):1366-1367. doi: 10.1164/rccm.202201-0042LE. Am J Respir Crit Care Med. 2022. PMID: 35358029 Free PMC article. No abstract available.

74

Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D.

Hoppe JE, Wagner BD, Kirk Harris J, Rowe SM, Heltshe SL, DeBoer EM, Sagel SD. Hoppe JE, et al. Among authors: rowe sm. J Cyst Fibros. 2022 Nov;21(6):950-958. doi: 10.1016/j.jcf.2022.03.012. Epub 2022 Apr 16. J Cyst Fibros. 2022. PMID: 35440409 Free PMC article.

75

Changes in Glucose Breath Test in Cystic Fibrosis Patients Treated With 1 Month of Lumacaftor/Ivacaftor.

Gabel ME, Wang H, Gelfond D, Roach C, Rowe SM, Clancy JP, Sagel SD, Borowitz D; PROSPECT GIFT Sub-study Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Gabel ME, et al. Among authors: rowe sm. J Pediatr Gastroenterol Nutr. 2022 Jul 1;75(1):42-47. doi: 10.1097/MPG.0000000000003459. Epub 2022 Apr 20. J Pediatr Gastroenterol Nutr. 2022. PMID: 35442228

76

Plasma and cellular ivacaftor concentrations in patients with cystic fibrosis.

Guimbellot JS, Ryan KJ, Anderson JD, Parker KL, Victoria Odom L, Rowe SM, Acosta EP. Guimbellot JS, et al. Among authors: rowe sm. Pediatr Pulmonol. 2022 Nov;57(11):2745-2753. doi: 10.1002/ppul.26093. Epub 2022 Aug 17. Pediatr Pulmonol. 2022. PMID: 35927224 Free PMC article.

77

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI.

Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, Narkewicz MR, Nichols DP, Heltshe SL, Donaldson SH, Frederick CA, Kelly A, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Solomon GM, Stalvey MS, Clancy JP, Rowe SM, Freedman SD; Promise Study Group. Schwarzenberg SJ, et al. Among authors: rowe sm. J Cyst Fibros. 2023 Mar;22(2):282-289. doi: 10.1016/j.jcf.2022.10.003. Epub 2022 Oct 21. J Cyst Fibros. 2023. PMID: 36280527 Free PMC article.

78

Red ginseng aqueous extract improves mucociliary transport dysfunction and histopathology in CF rat airways.

Cho DY, Zhang S, Skinner D, Koch CG, Smith MJ, Lim DJ, Grayson JW, Tearney GJ, Rowe SM, Woodworth BA. Cho DY, et al. Among authors: rowe sm. J Cyst Fibros. 2023 Nov;22(6):1113-1119. doi: 10.1016/j.jcf.2023.09.002. Epub 2023 Sep 12. J Cyst Fibros. 2023. PMID: 37704464 Free PMC article.

79

SNSP113 (PAAG) improves mucociliary transport and lung pathology in the Scnn1b-Tg murine model of CF lung disease.

Harris ES, Novak L, Fernandez-Petty CM, Lindgren NR, Baker SM, Birket SE, Rowe SM. Harris ES, et al. Among authors: rowe sm. J Cyst Fibros. 2023 Nov;22(6):1104-1112. doi: 10.1016/j.jcf.2023.08.011. Epub 2023 Sep 14. J Cyst Fibros. 2023. PMID: 37714777 Free PMC article.

80

Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis.

Donaldson SH, Corcoran TE, Pilewski JM, Mogayzel P, Laube BL, Boitet ER, Harris ES, Ceppe A, Edwards LJ, Zeman K, Wu J, Esther CR Jr, Nichols DP, Bennett WD, Rowe SM. Donaldson SH, et al. Among authors: rowe sm. J Cyst Fibros. 2024 Jan;23(1):155-160. doi: 10.1016/j.jcf.2023.10.010. Epub 2023 Oct 14. J Cyst Fibros. 2024. PMID: 37845149 Free PMC article.

81

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.

Donaldson SH, Corcoran TE, Pilewski JM, Laube BL, Mogayzel P, Ceppe A, Wu J, Zeman K, Rowe SM, Nichols DP, Gifford AH, Bennett WD, Mayer-Hamblett N; SIMPLIFY MCC Study teams. Donaldson SH, et al. Among authors: rowe sm. J Cyst Fibros. 2024 May;23(3):457-460. doi: 10.1016/j.jcf.2024.02.003. Epub 2024 Feb 13. J Cyst Fibros. 2024. PMID: 38355350 Free PMC article. Clinical Trial.

82

Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor.

Duong JT, Pope CE, Hayden HS, Miller C, Salipante SJ, Rowe SM, Solomon GM, Nichols D, Hoffman LR, Narkewicz MR, Green N. Duong JT, et al. Among authors: rowe sm. J Cyst Fibros. 2024 May;23(3):490-498. doi: 10.1016/j.jcf.2024.02.015. Epub 2024 Mar 6. J Cyst Fibros. 2024. PMID: 38448281 Free PMC article.

83

Toward in vivo bronchoscopic functional CFTR assessment using a short circuit current measurement probe.

Otuya DO, Liu Z, Joseph R, Hanafy MA, Vijaykumar K, Stanford D, Raju SV, Baker EH, Rowe SM, Tearney GJ, Solomon GM. Otuya DO, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2025 Feb 1;328(2):L313-L320. doi: 10.1152/ajplung.00137.2024. Epub 2024 Nov 27. Am J Physiol Lung Cell Mol Physiol. 2025. PMID: 39601216 Free article.

84

Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study.

Duong JT, Hayden HS, Verster AJ, Pope CE, Miller C, Kelsi Penewit, Salipante SJ, Rowe SM, Solomon GM, Nichols D, Kelly A, Schwarzenberg SJ, Freedman SD, Hoffman LR. Duong JT, et al. Among authors: rowe sm. J Cyst Fibros. 2025 Jun 6:S1569-1993(25)01487-0. doi: 10.1016/j.jcf.2025.05.006. Online ahead of print. J Cyst Fibros. 2025. PMID: 40483244 Free article.

85

Cystic fibrosis.

Rowe SM, Miller S, Sorscher EJ. Rowe SM, et al. N Engl J Med. 2005 May 12;352(19):1992-2001. doi: 10.1056/NEJMra043184. N Engl J Med. 2005. PMID: 15888700 No abstract available.

86

Advances in cystic fibrosis therapies.

Rowe SM, Clancy JP. Rowe SM, et al. Curr Opin Pediatr. 2006 Dec;18(6):604-13. doi: 10.1097/MOP.0b013e3280109b90. Curr Opin Pediatr. 2006. PMID: 17099358 Review.

87

No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.

Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, Mayer-Hamblett N, Ramsey B. Clancy JP, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2007 Jul;37(1):57-66. doi: 10.1165/rcmb.2006-0173OC. Epub 2007 Mar 8. Am J Respir Cell Mol Biol. 2007. PMID: 17347447 Free PMC article. Clinical Trial.

88

Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials.

Rowe SM, Accurso F, Clancy JP. Rowe SM, et al. Proc Am Thorac Soc. 2007 Aug 1;4(4):387-98. doi: 10.1513/pats.200703-043BR. Proc Am Thorac Soc. 2007. PMID: 17652506 Free PMC article. Review.

89

Genetic and reproductive knowledge among adolescents and adults with cystic fibrosis.

Houser GH, Holt CL, Clancy JP, Leon K, Rowe SM, Gaggar A, Gutierrez HH, Young KR, Robin NH. Houser GH, et al. Among authors: rowe sm. Chest. 2008 Jun;133(6):1533. doi: 10.1378/chest.08-0516. Chest. 2008. PMID: 18574307 No abstract available.

90

Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.

Sloane PA, Rowe SM. Sloane PA, et al. Among authors: rowe sm. Curr Opin Pulm Med. 2010 Nov;16(6):591-7. doi: 10.1097/MCP.0b013e32833f1d00. Curr Opin Pulm Med. 2010. PMID: 20829696 Free PMC article. Review.

91

Extensive surgical and comprehensive postoperative medical management for cystic fibrosis chronic rhinosinusitis.

Virgin FW, Rowe SM, Wade MB, Gaggar A, Leon KJ, Young KR, Woodworth BA. Virgin FW, et al. Among authors: rowe sm. Am J Rhinol Allergy. 2012 Jan-Feb;26(1):70-5. doi: 10.2500/ajra.2012.26.3705. Am J Rhinol Allergy. 2012. PMID: 22391086 Free PMC article.

92

Progress in cystic fibrosis and the CF Therapeutics Development Network.

Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW. Rowe SM, et al. Thorax. 2012 Oct;67(10):882-90. doi: 10.1136/thoraxjnl-2012-202550. Thorax. 2012. PMID: 22960984 Free PMC article.

93

Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.

Rowe SM, Reeves G, Hathorne H, Solomon GM, Abbi S, Renard D, Lock R, Zhou P, Danahay H, Clancy JP, Waltz DA. Rowe SM, et al. Chest. 2013 Jul;144(1):200-207. doi: 10.1378/chest.12-2431. Chest. 2013. PMID: 23412700 Free PMC article. Clinical Trial.

94

Cystic fibrosis transmembrane regulator correctors and potentiators.

Rowe SM, Verkman AS. Rowe SM, et al. Cold Spring Harb Perspect Med. 2013 Jul 1;3(7):a009761. doi: 10.1101/cshperspect.a009761. Cold Spring Harb Perspect Med. 2013. PMID: 23818513 Free PMC article. Review.

95

Cigarette smoke and CFTR: implications in the pathogenesis of COPD.

Rab A, Rowe SM, Raju SV, Bebok Z, Matalon S, Collawn JF. Rab A, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2013 Oct 15;305(8):L530-41. doi: 10.1152/ajplung.00039.2013. Epub 2013 Aug 9. Am J Physiol Lung Cell Mol Physiol. 2013. PMID: 23934925 Free PMC article. Review.

96

Understanding the relationship between sweat chloride and lung function in cystic fibrosis.

Heltshe SL, Mayer-Hamblett N, Rowe SM. Heltshe SL, et al. Among authors: rowe sm. Chest. 2013 Oct;144(4):1418. doi: 10.1378/chest.13-1320. Chest. 2013. PMID: 24081360 Free PMC article. No abstract available.

97

Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis.

Raju SV, Tate JH, Peacock SK, Fang P, Oster RA, Dransfield MT, Rowe SM. Raju SV, et al. Among authors: rowe sm. Respir Res. 2014 Feb 11;15(1):18. doi: 10.1186/1465-9921-15-18. Respir Res. 2014. PMID: 24517344 Free PMC article.

98

Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease.

Courville CA, Tidwell S, Liu B, Accurso FJ, Dransfield MT, Rowe SM. Courville CA, et al. Among authors: rowe sm. Respir Res. 2014 Feb 25;15(1):25. doi: 10.1186/1465-9921-15-25. Respir Res. 2014. PMID: 24568560 Free PMC article.

99

Porcine nasal epithelial cultures for studies of cystic fibrosis sinusitis.

Dean N, Ranganath NK, Jones B, Zhang S, Skinner D, Rowe SM, Sorscher EJ, Woodworth BA. Dean N, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2014 Jul;4(7):565-70. doi: 10.1002/alr.21335. Epub 2014 Apr 14. Int Forum Allergy Rhinol. 2014. PMID: 24733748 Free PMC article.

100

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group. Kerem E, et al. Among authors: rowe sm. Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15. Lancet Respir Med. 2014. PMID: 24836205 Free PMC article. Clinical Trial.

101

Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors.

Schuster BS, Kim AJ, Kays JC, Kanzawa MM, Guggino WB, Boyle MP, Rowe SM, Muzyczka N, Suk JS, Hanes J. Schuster BS, et al. Among authors: rowe sm. Mol Ther. 2014 Aug;22(8):1484-1493. doi: 10.1038/mt.2014.89. Epub 2014 May 29. Mol Ther. 2014. PMID: 24869933 Free PMC article.

102

Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients.

Schwiebert LM, Estell K, Meadows T, Thannickal VJ, Rowe S, Sorscher EJ, Harris WT, Gaggar A, Dransfield M, de Andrade JA. Schwiebert LM, et al. Clin Transl Sci. 2014 Aug;7(4):336-41. doi: 10.1111/cts.12161. Epub 2014 May 29. Clin Transl Sci. 2014. PMID: 24889057 Free PMC article.

103

Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.

Wheatley CM, Baker SE, Morgan MA, Martinez MG, Liu B, Rowe SM, Morgan WJ, Wong EC, Karpen SR, Snyder EM. Wheatley CM, et al. Among authors: rowe sm. Respir Med. 2015 Aug;109(8):1001-11. doi: 10.1016/j.rmed.2015.05.018. Epub 2015 May 23. Respir Med. 2015. PMID: 26077038 Free PMC article. Clinical Trial.

104

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.

Solomon GM, Marshall SG, Ramsey BW, Rowe SM. Solomon GM, et al. Among authors: rowe sm. Pediatr Pulmonol. 2015 Oct;50 Suppl 40(0 40):S3-S13. doi: 10.1002/ppul.23240. Epub 2015 Jun 19. Pediatr Pulmonol. 2015. PMID: 26097168 Free PMC article. Review.

105

Recovery of Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction after Smoking Cessation.

Courville CA, Raju SV, Liu B, Accurso FJ, Dransfield MT, Rowe SM. Courville CA, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2015 Dec 15;192(12):1521-4. doi: 10.1164/rccm.201502-0396LE. Am J Respir Crit Care Med. 2015. PMID: 26669476 Free PMC article. No abstract available.

106

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus Clearance.

Raju SV, Solomon GM, Dransfield MT, Rowe SM. Raju SV, et al. Among authors: rowe sm. Clin Chest Med. 2016 Mar;37(1):147-58. doi: 10.1016/j.ccm.2015.11.003. Epub 2015 Dec 24. Clin Chest Med. 2016. PMID: 26857776 Free PMC article. Review.

107

Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.

Mutyam V, Du M, Xue X, Keeling KM, White EL, Bostwick JR, Rasmussen L, Liu B, Mazur M, Hong JS, Falk Libby E, Liang F, Shang H, Mense M, Suto MJ, Bedwell DM, Rowe SM. Mutyam V, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2016 Nov 1;194(9):1092-1103. doi: 10.1164/rccm.201601-0154OC. Am J Respir Crit Care Med. 2016. PMID: 27104944 Free PMC article.

108

Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.

Solomon GM, Raju SV, Dransfield MT, Rowe SM. Solomon GM, et al. Among authors: rowe sm. Ann Am Thorac Soc. 2016 Apr;13 Suppl 2(Suppl 2):S169-76. doi: 10.1513/AnnalsATS.201509-601KV. Ann Am Thorac Soc. 2016. PMID: 27115953 Free PMC article. Review.

109

Cystic fibrosis.

Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Ratjen F, et al. Among authors: rowe sm. Nat Rev Dis Primers. 2015 May 14;1:15010. doi: 10.1038/nrdp.2015.10. Nat Rev Dis Primers. 2015. PMID: 27189798 Free PMC article. Review.

110

Toward inclusive therapy with CFTR modulators: Progress and challenges.

Guimbellot J, Sharma J, Rowe SM. Guimbellot J, et al. Among authors: rowe sm. Pediatr Pulmonol. 2017 Nov;52(S48):S4-S14. doi: 10.1002/ppul.23773. Epub 2017 Sep 7. Pediatr Pulmonol. 2017. PMID: 28881097 Free PMC article. Review.

111

Roflumilast reverses CFTR-mediated ion transport dysfunction in cigarette smoke-exposed mice.

Raju SV, Rasmussen L, Sloane PA, Tang LP, Libby EF, Rowe SM. Raju SV, et al. Among authors: rowe sm. Respir Res. 2017 Sep 18;18(1):173. doi: 10.1186/s12931-017-0656-0. Respir Res. 2017. PMID: 28923049 Free PMC article.

112

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.

Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT; VX11-661-101 Study Group. Donaldson SH, et al. Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC. Am J Respir Crit Care Med. 2018. PMID: 28930490 Free PMC article. Clinical Trial.

113

The therapeutic potential of CFTR modulators for COPD and other airway diseases.

Solomon GM, Fu L, Rowe SM, Collawn JF. Solomon GM, et al. Among authors: rowe sm. Curr Opin Pharmacol. 2017 Jun;34:132-139. doi: 10.1016/j.coph.2017.09.013. Epub 2017 Nov 10. Curr Opin Pharmacol. 2017. PMID: 29132121 Free PMC article. Review.

114

Development of an airway mucus defect in the cystic fibrosis rat.

Birket SE, Davis JM, Fernandez CM, Tuggle KL, Oden AM, Chu KK, Tearney GJ, Fanucchi MV, Sorscher EJ, Rowe SM. Birket SE, et al. Among authors: rowe sm. JCI Insight. 2018 Jan 11;3(1):e97199. doi: 10.1172/jci.insight.97199. eCollection 2018 Jan 11. JCI Insight. 2018. PMID: 29321377 Free PMC article.

115

Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients.

Garcia BA, Carden JL, Goodwin DL, Smith TA, Gaggar A, Leon K, Antony VB, Rowe SM, Solomon GM. Garcia BA, et al. Among authors: rowe sm. BMC Pulm Med. 2018 Feb 14;18(1):35. doi: 10.1186/s12890-018-0594-8. BMC Pulm Med. 2018. PMID: 29444656 Free PMC article.

116

Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction and Radiographic Bronchiectasis in Current and Former Smokers: A Cross-Sectional Study.

Teerapuncharoen K, Wells JM, Raju SV, Raraigh KS, Atalar Aksit M, Cutting GR, Rasmussen L, Nath PH, Bhatt SP, Solomon GM, Dransfield MT, Rowe SM. Teerapuncharoen K, et al. Among authors: rowe sm. Ann Am Thorac Soc. 2019 Jan;16(1):150-153. doi: 10.1513/AnnalsATS.201805-325RL. Ann Am Thorac Soc. 2019. PMID: 30230364 Free PMC article. No abstract available.

117

Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats.

Plyler ZE, Birket SE, Schultz BD, Hong JS, Rowe SM, Petty CF, Crowley MR, Crossman DK, Schoeb TR, Sorscher EJ. Plyler ZE, et al. Among authors: rowe sm. Mech Dev. 2019 Feb;155:15-26. doi: 10.1016/j.mod.2018.10.002. Epub 2018 Nov 2. Mech Dev. 2019. PMID: 30391480 Free PMC article.

118

A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.

Fernandez-Petty CM, Hughes GW, Bowers HL, Watson JD, Rosen BH, Townsend SM, Santos C, Ridley CE, Chu KK, Birket SE, Li Y, Leung HM, Mazur M, Garcia BA, Evans TIA, Libby EF, Hathorne H, Hanes J, Tearney GJ, Clancy JP, Engelhardt JF, Swords WE, Thornton DJ, Wiesmann WP, Baker SM, Rowe SM. Fernandez-Petty CM, et al. Among authors: rowe sm. JCI Insight. 2019 Apr 18;4(8):e125954. doi: 10.1172/jci.insight.125954. eCollection 2019 Apr 18. JCI Insight. 2019. PMID: 30996141 Free PMC article.

119

Intranasal micro-optical coherence tomography imaging for cystic fibrosis studies.

Leung HM, Birket SE, Hyun C, Ford TN, Cui D, Solomon GM, Shei RJ, Adewale AT, Lenzie AR, Fernandez-Petty CM, Zheng H, Palermo JH, Cho DY, Woodworth BA, Yonker LM, Hurley BP, Rowe SM, Tearney GJ. Leung HM, et al. Among authors: rowe sm. Sci Transl Med. 2019 Aug 7;11(504):eaav3505. doi: 10.1126/scitranslmed.aav3505. Sci Transl Med. 2019. PMID: 31391319 Free PMC article. Clinical Trial.

120

Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males.

Secunda KE, Guimbellot JS, Jovanovic B, Heltshe SL, Sagel SD, Rowe SM, Jain M. Secunda KE, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2020 Apr 15;201(8):996-998. doi: 10.1164/rccm.201909-1845LE. Am J Respir Crit Care Med. 2020. PMID: 31841644 Free PMC article. No abstract available.

121

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

Mall MA, Mayer-Hamblett N, Rowe SM. Mall MA, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2020 May 15;201(10):1193-1208. doi: 10.1164/rccm.201910-1943SO. Am J Respir Crit Care Med. 2020. PMID: 31860331 Free PMC article. Review.

122

Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis.

Lim DJ, McCormick J, Skinner D, Zhang S, Elder JB, McLemore JG, Allen M, West JM, Grayson JW, Rowe SM, Woodworth BA, Cho DY. Lim DJ, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2020 Apr;10(4):481-488. doi: 10.1002/alr.22514. Epub 2019 Dec 23. Int Forum Allergy Rhinol. 2020. PMID: 31872532 Free PMC article.

123

Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation. Reply.

Jain R, Middleton PG, Rowe SM. Jain R, et al. Among authors: rowe sm. N Engl J Med. 2020 Feb 13;382(7):684. doi: 10.1056/NEJMc1916747. N Engl J Med. 2020. PMID: 32053311 No abstract available.

124

Pulmonary artery enlargement is associated with pulmonary hypertension and decreased survival in severe cystic fibrosis: A cohort study.

Zouk AN, Gulati S, Xing D, Wille KM, Rowe SM, Wells JM. Zouk AN, et al. Among authors: rowe sm. PLoS One. 2020 Feb 20;15(2):e0229173. doi: 10.1371/journal.pone.0229173. eCollection 2020. PLoS One. 2020. PMID: 32078644 Free PMC article.

125

Novel Therapy of Bicarbonate, Glutathione, and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport.

Adewale AT, Falk Libby E, Fu L, Lenzie A, Boitet ER, Birket SE, Petty CF, Johns JD, Mazur M, Tearney GJ, Copeland D, Durham C, Rowe SM. Adewale AT, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2020 Sep;63(3):362-373. doi: 10.1165/rcmb.2019-0287OC. Am J Respir Cell Mol Biol. 2020. PMID: 32374624 Free PMC article.

126

Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial.

Rowe SM, Jones I, Dransfield MT, Haque N, Gleason S, Hayes KA, Kulmatycki K, Yates DP, Danahay H, Gosling M, Rowlands DJ, Grant SS. Rowe SM, et al. Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409. doi: 10.2147/COPD.S257474. eCollection 2020. Int J Chron Obstruct Pulmon Dis. 2020. PMID: 33116455 Free PMC article. Clinical Trial.

127

Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.

Mutyam V, Sharma J, Li Y, Peng N, Chen J, Tang LP, Falk Libby E, Singh AK, Conrath K, Rowe SM. Mutyam V, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2021 May;64(5):604-616. doi: 10.1165/rcmb.2019-0291OC. Am J Respir Cell Mol Biol. 2021. PMID: 33616476 Free PMC article.

128

Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.

Kaza N, Lin VY, Stanford D, Hussain SS, Falk Libby E, Kim H, Borgonovi M, Conrath K, Mutyam V, Byzek SA, Tang LP, Trombley JE, Rasmussen L, Schoeb T, Leung HM, Tearney GJ, Raju SV, Rowe SM. Kaza N, et al. Among authors: rowe sm. Eur Respir J. 2022 Jul 13;60(1):2101581. doi: 10.1183/13993003.01581-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34916262 Free PMC article.

129

Lessons from other fields of medicine, Part 2: Cystic fibrosis.

Vijaykumar K, Rowe SM. Vijaykumar K, et al. Among authors: rowe sm. Handb Clin Neurol. 2023;192:119-130. doi: 10.1016/B978-0-323-85538-9.00006-7. Handb Clin Neurol. 2023. PMID: 36796937 Review.

130

Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis.

Vijaykumar K, Leung HM, Barrios A, Wade J, Hathorne HY, Nichols DP, Tearney GJ, Rowe SM, Solomon GM. Vijaykumar K, et al. Among authors: rowe sm. Heliyon. 2024 Apr 16;10(8):e29188. doi: 10.1016/j.heliyon.2024.e29188. eCollection 2024 Apr 30. Heliyon. 2024. PMID: 38681615 Free PMC article.

131

Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cells.

Tanjala AC, Jiang JX, Eckford PDW, Ramjeesingh M, Li C, Huan LJ, Langeveld G, Townsend C, Paone DV, Busch-Petersen J, Pekhletski R, Tang L, Raju V, Rowe SM, Bear CE. Tanjala AC, et al. Among authors: rowe sm. Respir Res. 2024 Jul 10;25(1):269. doi: 10.1186/s12931-024-02889-w. Respir Res. 2024. PMID: 38982492 Free PMC article.

132

Ivacaftor for Chronic Obstructive Pulmonary Disease - Results from a Phase 2, Randomized Controlled Trial.

Vijaykumar K, Solomon GM, Guimbellot J, Acosta EP, Bhambhavni PG, White S, Kim H, Raju SV, Rasmussen LW, Harris N, Liu B, Hathorne H, Rowe SM, Dransfield MT. Vijaykumar K, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2024 Sep 24;211(5):823-31. doi: 10.1164/rccm.202407-1302OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39316773

133

Glycemia and Insulin Secretion in Cystic Fibrosis Two Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO.

Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Narkewicz MR, Rowe SM, Sagel SD, Schwarzenberg SJ, Solomon GM, Stalvey MS, Kelly A. Chan CL, et al. Among authors: rowe sm. J Clin Endocrinol Metab. 2024 Dec 9:dgae857. doi: 10.1210/clinem/dgae857. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39657947

134

Potential role of high-mobility group box 1 in cystic fibrosis airway disease.

Rowe SM, Jackson PL, Liu G, Hardison M, Livraghi A, Solomon GM, McQuaid DB, Noerager BD, Gaggar A, Clancy JP, O'Neal W, Sorscher EJ, Abraham E, Blalock JE. Rowe SM, et al. Am J Respir Crit Care Med. 2008 Oct 15;178(8):822-31. doi: 10.1164/rccm.200712-1894OC. Epub 2008 Jul 24. Am J Respir Crit Care Med. 2008. PMID: 18658107 Free PMC article.

135

Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens.

Havasi V, Rowe SM, Kolettis PN, Dayangac D, Sahin A, Grangeia A, Carvalho F, Barros A, Sousa M, Bassas L, Casals T, Sorscher EJ. Havasi V, et al. Among authors: rowe sm. Fertil Steril. 2010 Nov;94(6):2122-7. doi: 10.1016/j.fertnstert.2009.11.044. Epub 2010 Jan 25. Fertil Steril. 2010. PMID: 20100616 Free PMC article.

136

Nasal potential difference measurements to assess CFTR ion channel activity.

Rowe SM, Clancy JP, Wilschanski M. Rowe SM, et al. Methods Mol Biol. 2011;741:69-86. doi: 10.1007/978-1-61779-117-8_6. Methods Mol Biol. 2011. PMID: 21594779 Free PMC article.

137

Regulatory domain phosphorylation to distinguish the mechanistic basis underlying acute CFTR modulators.

Pyle LC, Ehrhardt A, Mitchell LH, Fan L, Ren A, Naren AP, Li Y, Clancy JP, Bolger GB, Sorscher EJ, Rowe SM. Pyle LC, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L587-97. doi: 10.1152/ajplung.00465.2010. Epub 2011 Jul 1. Am J Physiol Lung Cell Mol Physiol. 2011. PMID: 21724857 Free PMC article.

138

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. Ramsey BW, et al. Among authors: rowe sm. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185. N Engl J Med. 2011. PMID: 22047557 Free PMC article. Clinical Trial.

139

Quercetin increases cystic fibrosis transmembrane conductance regulator-mediated chloride transport and ciliary beat frequency: therapeutic implications for chronic rhinosinusitis.

Zhang S, Smith N, Schuster D, Azbell C, Sorscher EJ, Rowe SM, Woodworth BA. Zhang S, et al. Among authors: rowe sm. Am J Rhinol Allergy. 2011 Sep-Oct;25(5):307-12. doi: 10.2500/ajra.2011.25.3643. Am J Rhinol Allergy. 2011. PMID: 22186243 Free PMC article.

140

Comparison of cystic fibrosis transmembrane conductance regulator (CFTR) and ciliary beat frequency activation by the CFTR Modulators Genistein, VRT-532, and UCCF-152 in primary sinonasal epithelial cultures.

Conger BT, Zhang S, Skinner D, Hicks SB, Sorscher EJ, Rowe SM, Woodworth BA. Conger BT, et al. Among authors: rowe sm. JAMA Otolaryngol Head Neck Surg. 2013 Aug 1;139(8):822-7. doi: 10.1001/jamaoto.2013.3917. JAMA Otolaryngol Head Neck Surg. 2013. PMID: 23949358 Free PMC article.

141

Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.

Lambert JA, Raju SV, Tang LP, McNicholas CM, Li Y, Courville CA, Farris RF, Coricor GE, Smoot LH, Mazur MM, Dransfield MT, Bolger GB, Rowe SM. Lambert JA, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2014 Mar;50(3):549-58. doi: 10.1165/rcmb.2013-0228OC. Am J Respir Cell Mol Biol. 2014. PMID: 24106801 Free PMC article.

142

Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation.

Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, Sicilian L, Konstan M, Tullis E, Roach RN, Griffin K, Joseloff E, Borowitz D. Gelfond D, et al. Among authors: rowe sm. Clin Transl Gastroenterol. 2017 Mar 16;8(3):e81. doi: 10.1038/ctg.2017.10. Clin Transl Gastroenterol. 2017. PMID: 28300821 Free PMC article.

143

Codon bias and the folding dynamics of the cystic fibrosis transmembrane conductance regulator.

Bartoszewski R, Króliczewski J, Piotrowski A, Jasiecka AJ, Bartoszewska S, Vecchio-Pagan B, Fu L, Sobolewska A, Matalon S, Cutting GR, Rowe SM, Collawn JF. Bartoszewski R, et al. Among authors: rowe sm. Cell Mol Biol Lett. 2016 Oct 19;21:23. doi: 10.1186/s11658-016-0025-x. eCollection 2016. Cell Mol Biol Lett. 2016. PMID: 28536625 Free PMC article. Review.

144

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD).

Solomon GM, Bronsveld I, Hayes K, Wilschanski M, Melotti P, Rowe SM, Sermet-Gaudelus I. Solomon GM, et al. Among authors: rowe sm. J Vis Exp. 2018 Sep 13;(139):57006. doi: 10.3791/57006. J Vis Exp. 2018. PMID: 30272672 Free PMC article.

145

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.

Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Taylor-Cousar JL, et al. Among authors: rowe sm. ERJ Open Res. 2019 Jun 17;5(2):00082-2019. doi: 10.1183/23120541.00082-2019. eCollection 2019 Apr. ERJ Open Res. 2019. PMID: 31218221 Free PMC article.

146

Excess mucus viscosity and airway dehydration impact COPD airway clearance.

Lin VY, Kaza N, Birket SE, Kim H, Edwards LJ, LaFontaine J, Liu L, Mazur M, Byzek SA, Hanes J, Tearney GJ, Raju SV, Rowe SM. Lin VY, et al. Among authors: rowe sm. Eur Respir J. 2020 Jan 30;55(1):1900419. doi: 10.1183/13993003.00419-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31672759 Free PMC article.

147

A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay.

Sharma J, Abbott J, Klaskala L, Zhao G, Birket SE, Rowe SM. Sharma J, et al. Among authors: rowe sm. Front Physiol. 2020 Dec 16;11:611294. doi: 10.3389/fphys.2020.611294. eCollection 2020. Front Physiol. 2020. PMID: 33391025 Free PMC article.

148

Inhaled high molecular weight hyaluronan ameliorates respiratory failure in acute COPD exacerbation: a pilot study.

Galdi F, Pedone C, McGee CA, George M, Rice AB, Hussain SS, Vijaykumar K, Boitet ER, Tearney GJ, McGrath JA, Brown AR, Rowe SM, Incalzi RA, Garantziotis S. Galdi F, et al. Among authors: rowe sm. Respir Res. 2021 Feb 1;22(1):30. doi: 10.1186/s12931-020-01610-x. Respir Res. 2021. PMID: 33517896 Free PMC article. Clinical Trial.

149

Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.

Uluer AZ, MacGregor G, Azevedo P, Indihar V, Keating C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Rubenstein RC, Taylor-Cousar JL, Tullis E, Yonker LM, Chu C, Lam AP, Nair N, Sosnay PR, Tian S, Van Goor F, Viswanathan L, Waltz D, Wang LT, Xi Y, Billings J, Horsley A; VX18-121-101; VX18-561-101 Study Groups. Uluer AZ, et al. Among authors: rowe sm. Lancet Respir Med. 2023 Jun;11(6):550-562. doi: 10.1016/S2213-2600(22)00504-5. Epub 2023 Feb 23. Lancet Respir Med. 2023. PMID: 36842446 Free article. Clinical Trial.

150

Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.

Mall MA, Criner GJ, Miravitlles M, Rowe SM, Vogelmeier CF, Rowlands DJ, Schoenberger M, Altman P. Mall MA, et al. Among authors: rowe sm. Eur Respir J. 2023 Apr 1;61(4):2201307. doi: 10.1183/13993003.01307-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 37003609 Free PMC article. Review.

151

Reduced sialylation of airway mucin impairs mucus transport by altering the biophysical properties of mucin.

Harris ES, McIntire HJ, Mazur M, Schulz-Hildebrandt H, Leung HM, Tearney GJ, Krick S, Rowe SM, Barnes JW. Harris ES, et al. Among authors: rowe sm. Sci Rep. 2024 Jul 17;14(1):16568. doi: 10.1038/s41598-024-66510-2. Sci Rep. 2024. PMID: 39019950 Free PMC article.

152

Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment.

Morgan SJ, Coulter E, Betts HL, Solomon GM, Clancy JP, Rowe SM, Nichols DP, Singh PK; PROMISE-Micro Study Group. Morgan SJ, et al. Among authors: rowe sm. J Clin Invest. 2024 Sep 5;134(20):e184171. doi: 10.1172/JCI184171. J Clin Invest. 2024. PMID: 39235967 Free PMC article. No abstract available.

153

Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.

Rowe SM, Clancy JP. Rowe SM, et al. BioDrugs. 2009;23(3):165-74. doi: 10.2165/00063030-200923030-00003. BioDrugs. 2009. PMID: 19627168 Review.

154

Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue.

Pyle LC, Fulton JC, Sloane PA, Backer K, Mazur M, Prasain J, Barnes S, Clancy JP, Rowe SM. Pyle LC, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2010 Nov;43(5):607-16. doi: 10.1165/rcmb.2009-0281OC. Epub 2009 Dec 30. Am J Respir Cell Mol Biol. 2010. PMID: 20042712 Free PMC article.

155

An international randomized multicenter comparison of nasal potential difference techniques.

Solomon GM, Konstan MW, Wilschanski M, Billings J, Sermet-Gaudelus I, Accurso F, Vermeulen F, Levin E, Hathorne H, Reeves G, Sabbatini G, Hill A, Mayer-Hamblett N, Ashlock M, Clancy JP, Rowe SM. Solomon GM, et al. Among authors: rowe sm. Chest. 2010 Oct;138(4):919-28. doi: 10.1378/chest.10-0179. Epub 2010 May 14. Chest. 2010. PMID: 20472865 Free PMC article. Clinical Trial.

156

Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.

Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, Buckley-Lanier J, Nudelman I, Belakhov V, Bebok Z, Schwiebert E, Baasov T, Bedwell DM. Rowe SM, et al. J Mol Med (Berl). 2011 Nov;89(11):1149-61. doi: 10.1007/s00109-011-0787-6. Epub 2011 Jul 22. J Mol Med (Berl). 2011. PMID: 21779978 Free PMC article.

157

A breath of fresh air.

Rowe SM, Clancy JP, Sorscher EJ. Rowe SM, et al. Sci Am. 2011 Aug;305(2):68-73. doi: 10.1038/scientificamerican0811-68. Sci Am. 2011. PMID: 21827128 No abstract available.

158

Characterization of defects in ion transport and tissue development in cystic fibrosis transmembrane conductance regulator (CFTR)-knockout rats.

Tuggle KL, Birket SE, Cui X, Hong J, Warren J, Reid L, Chambers A, Ji D, Gamber K, Chu KK, Tearney G, Tang LP, Fortenberry JA, Du M, Cadillac JM, Bedwell DM, Rowe SM, Sorscher EJ, Fanucchi MV. Tuggle KL, et al. Among authors: rowe sm. PLoS One. 2014 Mar 7;9(3):e91253. doi: 10.1371/journal.pone.0091253. eCollection 2014. PLoS One. 2014. PMID: 24608905 Free PMC article.

159

A ferret model of COPD-related chronic bronchitis.

Raju SV, Kim H, Byzek SA, Tang LP, Trombley JE, Jackson P, Rasmussen L, Wells JM, Libby EF, Dohm E, Winter L, Samuel SL, Zinn KR, Blalock JE, Schoeb TR, Dransfield MT, Rowe SM. Raju SV, et al. Among authors: rowe sm. JCI Insight. 2016 Sep 22;1(15):e87536. doi: 10.1172/jci.insight.87536. JCI Insight. 2016. PMID: 27699245 Free PMC article.

160

Klotho Inhibits Interleukin-8 Secretion from Cystic Fibrosis Airway Epithelia.

Krick S, Baumlin N, Aller SP, Aguiar C, Grabner A, Sailland J, Mendes E, Schmid A, Qi L, David NV, Geraghty P, King G, Birket SE, Rowe SM, Faul C, Salathe M. Krick S, et al. Among authors: rowe sm. Sci Rep. 2017 Oct 30;7(1):14388. doi: 10.1038/s41598-017-14811-0. Sci Rep. 2017. PMID: 29085059 Free PMC article.

161

Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis.

Brand JD, Lazrak A, Trombley JE, Shei RJ, Adewale AT, Tipper JL, Yu Z, Ashtekar AR, Rowe SM, Matalon S, Harrod KS. Brand JD, et al. Among authors: rowe sm. JCI Insight. 2018 Oct 18;3(20):e123467. doi: 10.1172/jci.insight.123467. JCI Insight. 2018. PMID: 30333319 Free PMC article.

162

Cystic Fibrosis Transmembrane Conductance Regulator: Roles in Chronic Obstructive Pulmonary Disease.

Dransfield M, Rowe S, Vogelmeier CF, Wedzicha J, Criner GJ, Han MK, Martinez FJ, Calverley P. Dransfield M, et al. Am J Respir Crit Care Med. 2022 Mar 15;205(6):631-640. doi: 10.1164/rccm.202109-2064TR. Am J Respir Crit Care Med. 2022. PMID: 34982651 Review.

163

Poly (acetyl, arginyl) glucosamine disrupts Pseudomonas aeruginosa biofilms and enhances bacterial clearance in a rat lung infection model.

Garcia BA, McDaniel MS, Loughran AJ, Johns JD, Narayanaswamy V, Fernandez Petty C, Birket SE, Baker SM, Barnaby R, Stanton BA, Foote JB, Rowe SM, Swords WE. Garcia BA, et al. Among authors: rowe sm. Microbiology (Reading). 2022 Jan;168(1):001121. doi: 10.1099/mic.0.001121. Microbiology (Reading). 2022. PMID: 35077346 Free PMC article.

164

Static mucus impairs bacterial clearance and allows chronic infection with Pseudomonas aeruginosa in the cystic fibrosis rat.

Henderson AG, Davis JM, Keith JD, Green ME, Oden AM, Rowe SM, Birket SE. Henderson AG, et al. Among authors: rowe sm. Eur Respir J. 2022 Sep 7;60(3):2101032. doi: 10.1183/13993003.01032-2021. Print 2022 Sep. Eur Respir J. 2022. PMID: 35115338 Free PMC article.

165

Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells.

Li C, Liu Z, Anderson J, Liu Z, Tang L, Li Y, Peng N, Chen J, Liu X, Fu L, Townes TM, Rowe SM, Bedwell DM, Guimbellot J, Zhao R. Li C, et al. Among authors: rowe sm. PLoS One. 2023 Nov 29;18(11):e0295009. doi: 10.1371/journal.pone.0295009. eCollection 2023. PLoS One. 2023. PMID: 38019847 Free PMC article.

166

Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.

Morgan SJ, Nichols DP, Ni W, Hong G, Salipante SJ, Solomon GM, Rowe SM, Clancy JP, Cramer RA, Singh PK. Morgan SJ, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2024 Nov 1;210(9):1155-1158. doi: 10.1164/rccm.202406-1128RL. Am J Respir Crit Care Med. 2024. PMID: 39189854 Free PMC article. No abstract available.

167

ACE-2 blockade and TMPRSS2 inhibition mitigate SARS-CoV-2 severity following cigarette smoke exposure in airway epithelial cells in vitro.

Hussain SS, Libby EF, Peabody Lever JE, Tipper JL, Phillips SE, Mazur M, Li Q, Campos-Gómez J, Harrod KS, Rowe SM. Hussain SS, et al. Among authors: rowe sm. Mol Ther Nucleic Acids. 2025 Jun 2;36(3):102580. doi: 10.1016/j.omtn.2025.102580. eCollection 2025 Sep 9. Mol Ther Nucleic Acids. 2025. PMID: 40612711 Free PMC article.

168

Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation.

Gaggar A, Rowe SM, Matthew H, Blalock JE. Gaggar A, et al. Among authors: rowe sm. Open Respir Med J. 2010 Mar 30;4:32-8. doi: 10.2174/1874306401004020032. Open Respir Med J. 2010. PMID: 20448817 Free PMC article.

169

Dab2 is a key regulator of endocytosis and post-endocytic trafficking of the cystic fibrosis transmembrane conductance regulator.

Fu L, Rab A, Tang LP, Rowe SM, Bebok Z, Collawn JF. Fu L, et al. Among authors: rowe sm. Biochem J. 2012 Jan 15;441(2):633-43. doi: 10.1042/BJ20111566. Biochem J. 2012. PMID: 21995445 Free PMC article.

170

Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.

Chung WJ, Goeckeler-Fried JL, Havasi V, Chiang A, Rowe SM, Plyler ZE, Hong JS, Mazur M, Piazza GA, Keeton AB, White EL, Rasmussen L, Weissman AM, Denny RA, Brodsky JL, Sorscher EJ. Chung WJ, et al. Among authors: rowe sm. PLoS One. 2016 Oct 12;11(10):e0163615. doi: 10.1371/journal.pone.0163615. eCollection 2016. PLoS One. 2016. PMID: 27732613 Free PMC article.

171

Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations.

Reeves EP, O'Dwyer CA, Dunlea DM, Wormald MR, Hawkins P, Alfares M, Kotton DN, Rowe SM, Wilson AA, McElvaney NG. Reeves EP, et al. Among authors: rowe sm. Am J Respir Crit Care Med. 2018 Oct 15;198(8):1099-1102. doi: 10.1164/rccm.201802-0338LE. Am J Respir Crit Care Med. 2018. PMID: 30011228 Free PMC article. No abstract available.

172

Heme scavenging reduces pulmonary endoplasmic reticulum stress, fibrosis, and emphysema.

Aggarwal S, Ahmad I, Lam A, Carlisle MA, Li C, Wells JM, Raju SV, Athar M, Rowe SM, Dransfield MT, Matalon S. Aggarwal S, et al. Among authors: rowe sm. JCI Insight. 2018 Nov 2;3(21):e120694. doi: 10.1172/jci.insight.120694. JCI Insight. 2018. PMID: 30385726 Free PMC article.

173

Vaporized E-Cigarette Liquids Induce Ion Transport Dysfunction in Airway Epithelia.

Lin VY, Fain MD, Jackson PL, Berryhill TF, Wilson LS, Mazur M, Barnes SJ, Blalock JE, Raju SV, Rowe SM. Lin VY, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2019 Aug;61(2):162-173. doi: 10.1165/rcmb.2017-0432OC. Am J Respir Cell Mol Biol. 2019. PMID: 30576219 Free PMC article.

174

The impact of Lactococcus lactis (probiotic nasal rinse) co-culture on growth of patient-derived strains of Pseudomonas aeruginosa.

Cho DY, Skinner D, Lim DJ, Mclemore JG, Koch CG, Zhang S, Swords WE, Hunter R, Crossman DK, Crowley MR, Grayson JW, Rowe SM, Woodworth BA. Cho DY, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2020 Apr;10(4):444-449. doi: 10.1002/alr.22521. Epub 2020 Jan 10. Int Forum Allergy Rhinol. 2020. PMID: 31922358 Free PMC article.

175

G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations.

Wang W, Fu L, Liu Z, Wen H, Rab A, Hong JS, Kirk KL, Rowe SM. Wang W, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2020 Nov 1;319(5):L770-L785. doi: 10.1152/ajplung.00262.2019. Epub 2020 Sep 2. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 32877225 Free PMC article.

176

Gaming Console Home-Based Exercise for Adults with Cystic Fibrosis: Study Protocol.

Lowman JD, Solomon GM, Rowe SM, Yuen HK. Lowman JD, et al. Among authors: rowe sm. Int J Caring Sci. 2020 Spring/Summer;13(2):1530-1540. Int J Caring Sci. 2020. PMID: 33163109 Free PMC article.

177

An ex vivo rat trachea model reveals abnormal airway physiology and a gland secretion defect in cystic fibrosis.

Harris E, Easter M, Ren J, Krick S, Barnes J, Rowe SM. Harris E, et al. Among authors: rowe sm. PLoS One. 2023 Oct 24;18(10):e0293367. doi: 10.1371/journal.pone.0293367. eCollection 2023. PLoS One. 2023. PMID: 37874846 Free PMC article.

178

Assessment of acquired mucociliary clearance defects using micro-optical coherence tomography.

Tipirneni KE, Grayson JW, Zhang S, Cho DY, Skinner DF, Lim DJ, Mackey C, Tearney GJ, Rowe SM, Woodworth BA. Tipirneni KE, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2017 Sep;7(9):920-925. doi: 10.1002/alr.21975. Epub 2017 Jun 28. Int Forum Allergy Rhinol. 2017. PMID: 28658531 Free PMC article.

179

Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat.

Stalvey MS, Havasi V, Tuggle KL, Wang D, Birket S, Rowe SM, Sorscher EJ. Stalvey MS, et al. Among authors: rowe sm. PLoS One. 2017 Nov 30;12(11):e0188497. doi: 10.1371/journal.pone.0188497. eCollection 2017. PLoS One. 2017. PMID: 29190650 Free PMC article.

180

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809.

Doiron JE, Le CA, Ody BK, Brace JB, Post SJ, Thacker NL, Hill HM, Breton GW, Mulder MJ, Chang S, Bridges TM, Tang L, Wang W, Rowe SM, Aller SG, Turlington M. Doiron JE, et al. Among authors: rowe sm. Chemistry. 2019 Mar 7;25(14):3662-3674. doi: 10.1002/chem.201805919. Epub 2019 Feb 11. Chemistry. 2019. PMID: 30650214 Free PMC article.

181

Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis.

Cho DY, Skinner D, Mackey C, Lampkin HB, Elder JB, Lim DJ, Zhang S, McCormick J, Tearney GJ, Rowe SM, Woodworth BA. Cho DY, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2019 Jun;9(6):629-637. doi: 10.1002/alr.22290. Epub 2019 Jan 18. Int Forum Allergy Rhinol. 2019. PMID: 30657641 Free PMC article.

182

Haemophilus influenzae persists in biofilm communities in a smoke-exposed ferret model of COPD.

Hunt BC, Stanford D, Xu X, Li J, Gaggar A, Rowe SM, Raju SV, Swords WE. Hunt BC, et al. Among authors: rowe sm. ERJ Open Res. 2020 Aug 11;6(3):00200-2020. doi: 10.1183/23120541.00200-2020. eCollection 2020 Jul. ERJ Open Res. 2020. PMID: 32802827 Free PMC article.

183

LPS decreases CFTR open probability and mucociliary transport through generation of reactive oxygen species.

Cho DY, Zhang S, Lazrak A, Skinner D, Thompson HM, Grayson J, Guroji P, Aggarwal S, Bebok Z, Rowe SM, Matalon S, Sorscher EJ, Woodworth BA. Cho DY, et al. Among authors: rowe sm. Redox Biol. 2021 Jul;43:101998. doi: 10.1016/j.redox.2021.101998. Epub 2021 Apr 30. Redox Biol. 2021. PMID: 33971543 Free PMC article.

184

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion.

Sharma J, Du M, Wong E, Mutyam V, Li Y, Chen J, Wangen J, Thrasher K, Fu L, Peng N, Tang L, Liu K, Mathew B, Bostwick RJ, Augelli-Szafran CE, Bihler H, Liang F, Mahiou J, Saltz J, Rab A, Hong J, Sorscher EJ, Mendenhall EM, Coppola CJ, Keeling KM, Green R, Mense M, Suto MJ, Rowe SM, Bedwell DM. Sharma J, et al. Among authors: rowe sm. Nat Commun. 2021 Jul 16;12(1):4358. doi: 10.1038/s41467-021-24575-x. Nat Commun. 2021. PMID: 34272367 Free PMC article.

185

Lumacaftor inhibits channel activity of rescued F508del cystic fibrosis transmembrane conductance regulator.

Ambrosetti AD, Hagedorn ZJ, Bono TR, Wen H, Nguyen R, Rodriguez-Cruz K, Ali J, Palacio H, Phillips AJ, Gilliland SD, Freeman AJ, Thompson J, Fu L, McNicholas CM, Rowe SM, Wang XR. Ambrosetti AD, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2025 Jun 1;328(6):L832-L843. doi: 10.1152/ajplung.00287.2024. Epub 2025 May 7. Am J Physiol Lung Cell Mol Physiol. 2025. PMID: 40331529 Free PMC article.

186

Restoration of W1282X CFTR activity by enhanced expression.

Rowe SM, Varga K, Rab A, Bebok Z, Byram K, Li Y, Sorscher EJ, Clancy JP. Rowe SM, et al. Am J Respir Cell Mol Biol. 2007 Sep;37(3):347-56. doi: 10.1165/rcmb.2006-0176OC. Epub 2007 May 31. Am J Respir Cell Mol Biol. 2007. PMID: 17541014 Free PMC article.

187

DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.

Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP. Rowe SM, et al. Pulm Pharmacol Ther. 2010 Aug;23(4):268-78. doi: 10.1016/j.pupt.2010.02.001. Epub 2010 Mar 10. Pulm Pharmacol Ther. 2010. PMID: 20226262 Free PMC article.

188

Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.

Xue X, Mutyam V, Tang L, Biswas S, Du M, Jackson LA, Dai Y, Belakhov V, Shalev M, Chen F, Schacht J, J Bridges R, Baasov T, Hong J, Bedwell DM, Rowe SM. Xue X, et al. Among authors: rowe sm. Am J Respir Cell Mol Biol. 2014 Apr;50(4):805-16. doi: 10.1165/rcmb.2013-0282OC. Am J Respir Cell Mol Biol. 2014. PMID: 24251786 Free PMC article.

189

Novel outcome measures for clinical trials in cystic fibrosis.

Tiddens HAWM, Puderbach M, Venegas JG, Ratjen F, Donaldson SH, Davis SD, Rowe SM, Sagel SD, Higgins M, Waltz DA. Tiddens HAWM, et al. Among authors: rowe sm. Pediatr Pulmonol. 2015 Mar;50(3):302-315. doi: 10.1002/ppul.23146. Epub 2014 Dec 30. Pediatr Pulmonol. 2015. PMID: 25641878 Free PMC article. Review.

190

Seeing cilia: imaging modalities for ciliary motion and clinical connections.

Peabody JE, Shei RJ, Bermingham BM, Phillips SE, Turner B, Rowe SM, Solomon GM. Peabody JE, et al. Among authors: rowe sm. Am J Physiol Lung Cell Mol Physiol. 2018 Jun 1;314(6):L909-L921. doi: 10.1152/ajplung.00556.2017. Epub 2018 Mar 1. Am J Physiol Lung Cell Mol Physiol. 2018. PMID: 29493257 Free PMC article. Review.

191

Particle-Tracking Microrheology Using Micro-Optical Coherence Tomography.

Chu KK, Mojahed D, Fernandez CM, Li Y, Liu L, Wilsterman EJ, Diephuis B, Birket SE, Bowers H, Martin Solomon G, Schuster BS, Hanes J, Rowe SM, Tearney GJ. Chu KK, et al. Among authors: rowe sm. Biophys J. 2016 Sep 6;111(5):1053-63. doi: 10.1016/j.bpj.2016.07.020. Biophys J. 2016. PMID: 27602733 Free PMC article.

192

Identification of the amino acids inserted during suppression of CFTR nonsense mutations and determination of their functional consequences.

Xue X, Mutyam V, Thakerar A, Mobley J, Bridges RJ, Rowe SM, Keeling KM, Bedwell DM. Xue X, et al. Among authors: rowe sm. Hum Mol Genet. 2017 Aug 15;26(16):3116-3129. doi: 10.1093/hmg/ddx196. Hum Mol Genet. 2017. PMID: 28575328 Free PMC article.

193

Muc5b overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice.

Hancock LA, Hennessy CE, Solomon GM, Dobrinskikh E, Estrella A, Hara N, Hill DB, Kissner WJ, Markovetz MR, Grove Villalon DE, Voss ME, Tearney GJ, Carroll KS, Shi Y, Schwarz MI, Thelin WR, Rowe SM, Yang IV, Evans CM, Schwartz DA. Hancock LA, et al. Among authors: rowe sm. Nat Commun. 2018 Dec 18;9(1):5363. doi: 10.1038/s41467-018-07768-9. Nat Commun. 2018. PMID: 30560893 Free PMC article.

194

Geometry-Dependent Spectroscopic Contrast in Deep Tissues.

Ge X, Tang H, Wang X, Liu X, Chen S, Wang N, Ni G, Yu X, Chen S, Liang H, Bo E, Wang L, Braganza CS, Xu C, Rowe SM, Tearney GJ, Liu L. Ge X, et al. Among authors: rowe sm. iScience. 2019 Sep 27;19:965-975. doi: 10.1016/j.isci.2019.08.046. Epub 2019 Aug 29. iScience. 2019. PMID: 31522119 Free PMC article.

195

Comparative transcriptomics in human COPD reveals dysregulated genes uniquely expressed in ferrets.

Hussain SS, Edwards YJK, Libby EF, Stanford D, Byzek SA, Sin DD, McDonald ML, Raju SV, Rowe SM. Hussain SS, et al. Among authors: rowe sm. Respir Res. 2022 Oct 10;23(1):277. doi: 10.1186/s12931-022-02198-0. Respir Res. 2022. PMID: 36217144 Free PMC article.

196

Glutathione and bicarbonate nanoparticles improve mucociliary transport in cystic fibrosis epithelia.

Cho DY, Rivers NJ, Lim DJ, Zhang S, Skinner D, Yang L, Menon AJ, Kelly OJ, Jones MP, Bicknell BT, Grayson JW, Harris E, Rowe SM, Woodworth BA. Cho DY, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2024 Jun;14(6):1026-1035. doi: 10.1002/alr.23301. Epub 2023 Nov 17. Int Forum Allergy Rhinol. 2024. PMID: 37975554 Free PMC article.

197

Hypoxia-induced cystic fibrosis transmembrane conductance regulator dysfunction is a universal mechanism underlying reduced mucociliary transport in sinusitis.

Cho DY, Zhang S, Norwood TG, Skinner D, Hollis TA, Ehrhardt ML, Yang LC, Lim DJ, Grayson JW, Lazrak A, Matalon S, Rowe SM, Woodworth BA. Cho DY, et al. Among authors: rowe sm. Int Forum Allergy Rhinol. 2024 Jun;14(6):1058-1069. doi: 10.1002/alr.23309. Epub 2023 Dec 11. Int Forum Allergy Rhinol. 2024. PMID: 38073611 Free PMC article.

198

Use of ferrets for electrophysiologic monitoring of ion transport.

Kaza N, Raju SV, Cadillac JM, Trombley JA, Rasmussen L, Tang L, Dohm E, Harrod KS, Rowe SM. Kaza N, et al. Among authors: rowe sm. PLoS One. 2017 Oct 27;12(10):e0186984. doi: 10.1371/journal.pone.0186984. eCollection 2017. PLoS One. 2017. PMID: 29077751 Free PMC article.

199

A revised airway epithelial hierarchy includes CFTR-expressing ionocytes.

Montoro DT, Haber AL, Biton M, Vinarsky V, Lin B, Birket SE, Yuan F, Chen S, Leung HM, Villoria J, Rogel N, Burgin G, Tsankov AM, Waghray A, Slyper M, Waldman J, Nguyen L, Dionne D, Rozenblatt-Rosen O, Tata PR, Mou H, Shivaraju M, Bihler H, Mense M, Tearney GJ, Rowe SM, Engelhardt JF, Regev A, Rajagopal J. Montoro DT, et al. Among authors: rowe sm. Nature. 2018 Aug;560(7718):319-324. doi: 10.1038/s41586-018-0393-7. Epub 2018 Aug 1. Nature. 2018. PMID: 30069044 Free PMC article.

200

The Effects of the Anti-aging Protein Klotho on Mucociliary Clearance.

Garth J, Easter M, Skylar Harris E, Sailland J, Kuenzi L, Chung S, Dennis JS, Baumlin N, Adewale AT, Rowe SM, King G, Faul C, Barnes JW, Salathe M, Krick S. Garth J, et al. Among authors: rowe sm. Front Med (Lausanne). 2020 Jan 24;6:339. doi: 10.3389/fmed.2019.00339. eCollection 2019. Front Med (Lausanne). 2020. PMID: 32039219 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters